Adaptimmune Ltd.
57c Milton Park
Abingdon
Oxfordshire
OX14 4RX
United Kingdom
Tel: +44-(0)-1235-438-642
Fax: +44-(0)-1235-438-607
Website: http://www.adaptimmune.com/
129 articles with Adaptimmune Ltd.
-
Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT
5/16/2022
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, is presenting preclinical proof-of-concept data from its second next-generation SPEAR T-cell targeting MAGE-A4, and novel tumor-infiltrating lymphocytes expressing IL-7 at the American Society of Gene & Cell Therapy annual meeting.
-
Adaptimmune Reports First Quarter 2022 Financial Results and Business Update
5/9/2022
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, reported financial results for the first quarter ended March 31, 2022 and provided a business update.
-
After guiding the commercial rollout of embattled Alzheimer’s drug Aduhelm for Biogen, Johanna Rossell has departed the company for a leadership role at Enzyvant.
-
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
1/26/2022
Adaptimmune Therapeutics plc today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022.
-
Adaptimmune said that afamitresgene autoleucel (afami-cel) had a significantly positive effect on patients diagnosed with myxoid/round cell liposarcoma (MRCLS) and advanced synovial sarcoma.
-
Adaptimmune Reports Third Quarter Financial Results and Business Update
11/4/2021
Adaptimmune Therapeutics plc today reported financial results for the third quarter ended September 30, 2021, and provided a business update.
-
Adaptimmune will be responsible for developing clinical T-cell candidates for the two companies through its induced pluripotent stem cell (iPSC) derived allogeneic platform.
-
Adaptimmune Reports Second Quarter 2021 Financial Results and Business Update
8/9/2021
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, reported financial results for the second quarter ended June 30, 2021 and provided a business update.
-
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5/19/2021
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel, at the American Society of Clinical Oncology congress.
-
Adaptimmune Reports First Quarter Financial Results and Business Update
5/6/2021
- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - - Enrollment momentum in SURPASS and ADP-A2AFP clinical trials increased in Q1 - - Astellas nominates second target as part of allogeneic co-development and co-commercialization agreement - - Financial guidance confirmed: funded into early 2023 -
-
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
4/27/2021
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy meeting.
-
Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021
4/22/2021
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the first quarter ended March 31, 2021, before the US markets open on Thursday, May 6, 2021. Following the announcement, the Company will host a live teleconference and webcast at 9:00 a.m. EDT (2:00 p.m. BST) that same day (details below).
-
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
2/25/2021
- Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers - - Reported compelling durable responses in patients with synovial sarcoma, and initial responses in lung, head and neck, liver, esophagogastric junction, and melanoma cancers confirming potential of SPEAR T-cells for solid tumors - -
-
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
11/9/2020
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, presented data from the dose escalation cohorts of its Phase 1 SURPASS trial using ADP-A2M4CD8 in a poster at the Society for the Immunotherapy of Cancer Conference.
-
Adaptimmune Reports Q3 Financial Results and Business Update
11/5/2020
- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation cohorts of the SURPASS trial to be presented at SITC - - Durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial to be presented at CTOS - - Virtual Investor Day planned for November 20, 2020 - - Financial guidance confirmed: funded into 2022 -
-
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
10/15/2020
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and product attributes from the SURPASS trial with ADPA2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor” by the Society for the Immunotherapy of Cancer (“SITC”) Conference
-
Adaptimmune Reports Q2 Financial Results and Business Update
8/6/2020
- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 - - Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - - Granted access to PRIority MEdicines (PRIME) regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma - - Completed public offering with net proceeds of approximately $244m; guidance confirmed: funded into 2022
-
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
7/22/2020
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below). The press release and the live webcast of the con
-
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares - June 04, 2020
6/4/2020
PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”). Adaptimmune sold a total of 23,575,000 ADSs at a price to the public of $11.00 per ADS, including 3,075,000 ADSs pursuant to the exercise in full by the underwriters of their option to p
-
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares - June 02, 2020
6/2/2020
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares at a price to the public of $11.00 per ADS.